Danaher Corporation (DHR): a potential bargain?

Buy — the crash looks like panic over a small, timing-related revenue delay while Danaher actually beat estimates and raised EPS guidance.

🔥 HOT Fundamentals68/100

Fell 11% in 1 trading day(s) — now $179.01

Why DHR dropped

Danaher reported Q2 2026 revenue and EPS that beat Wall Street estimates and raised full-year EPS guidance, but the stock still fell over 11% because it trimmed its core-revenue growth outlook after some biopharma customers delayed roughly $100 million of chromatography-resin shipments into 2027.

Fwd P/E 19.3Op margin 18.0%Rev growth 5.5%Debt/equity 50.5%Analyst upside 35.5%

How this scored 68/100

✅ Passes all 4 hard checks — profitable, cash-generative, and financially survivable.

✅ Makes money Net profit margin 15.9%

✅ Generates cash Free cash flow $4.5B

✅ Not drowning in debt Debt/equity 50.5% (limit 200%)

✅ Can pay its bills Current ratio 1.7 (needs 1+)

Bar length shows how much each metric is worth — a 10-point metric is twice as wide as a 5-point one. Hover any row for what it means.

Profitability Does it actually make money? 14/25

Operating margin 18.0% 6/9

Net profit margin 15.9% 6/8

Return on equity 7.6% 1/8

Growth Is it getting bigger, or dying? 19/25

Revenue growth 5.5% 3/9

Earnings growth 59.7% 8/8

Expected profit change 101.5% 8/8

Value Is it cheap right now? 16/25

Forward P/E 19.3 6/10

PEG ratio 1.3 5/8

Analyst target upside 35.5% 4/7

Balance sheet Will it survive? 19/25

Debt / equity 50.5% 8/10

Current ratio 1.7 3/8

Free cash flow $4.5B 7/7

🔒 Read the full AI analysis

Create a free account to unlock the bull case and the risks for DHR — plus today's other picks.

Analysis generated by SmartStonks's AI from public fundamentals and news, first flagged 2026-07-22. Research only — not financial advice.